Source
Rare Disease Advisor
Despite the proven efficacy of tafamidis in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), real-world treatment decisions often involve interdisciplinary boards and highlight the need for standardized criteria to guide therapy in early and advanced cases, according to a recent study published in Clinical Research in Cardiology.
News Url